MONCYTE Health Joins International Consortium for Earlier Diagnosis and Management of Familial Hypercholesterolemia – EUR 7 million Horizon Europe funded FH-EARLY project on world’s most common inherited metabolic disorder
HELSINKI, Finland (9 January 2025) – MONCYTE Health, developing proprietary technology to optimize treatment and prevention of cardiovascular disease, announces today that it has been selected to join a 4-year Horizon funded project as a core industrial partner. In this project MONCYTE Health is part of a consortium of 15 internationally leading institutions, working together to enable new strategies for earlier diagnosis and co-management of familial hypercholesterolemia (FH). FH is the world’s most common inherited metabolic disorder, affecting around 2.5 million Europeans
